Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck and Intercell have terminated Phase II/III clinical trial evaluating V710, an experimental vaccine targeting Staphylococcus aureus (S aureus) infection over safety concerns on the recommendation of independent Data Monitoring Committee (DMC).
Subscribe to our email newsletter
Previously, DMC asked Merck to terminate patient recruitment as the study failed to meet the formal futility criteria.
The decision was based on the data which showed overall mortality and multi-organ dysfunction that occurred with greater frequency in vaccine recipients, compared with placebo recipients.
Further, V710 did not show a statistically significant clinical benefit compared with a placebo.